42 results about "Solid Dose Form" patented technology

Disclosed herein are pharmaceutical oral solid dosage forms comprising a salt of liothyronin and a salt of levothyroxine, and methods of making and using the pharmaceutical oral solid dosage forms.

Described herein are dosage forms comprising the compound:wherein the dosage form can be a solid dosage form, a liquid dosage form, or a solid amorphous dispersion.

Provided herein are pharmaceutical formulations of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form. Also provided herein are methods of treating cancer comprising a pharmaceutical formulation of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form.

The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder.

This invention relates to pharmaceutical inclusion compounds, their preparation methods, and uses. Specifically, it provides a buggerfuran inclusion compound and its preparation method, wherein the inclusion compound comprises buggerfuran, cyclodextrin compounds, and optionally a high molecular weight polymer. This inclusion compound has a simple composition, high encapsulation efficiency, stability, and high safety, and can be used to prepare various liquid and solid dosage forms.

A solid dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API) is disclosed. Also provided are methods of treating a disease with the solid dosage form.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

The present invention relates to co-treated excipient compositions for solid dose pharmaceutical formulations. In addition, the present invention relates to a process for preparing the co-treated excipient composition and a solid dose pharmaceutical formulation containing the co-treated excipient composition.

Provided herein are compositions and methods relating to solid dosage forms comprising an absorption enhancer. The composition enhances mucosal penetration and absorption of the active ingredient.

The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The present invention relates to the use of co-processed excipients in continuous manufacturing of solid dosage forms.

A closed-system grinding syringe (10, 110) is provided for liquefying and delivering a solid dosage form (20), including a barrel (22), a fluid port (30) disposed on a bottom wall (28) of the barrel (22), and a plunger (32). A head (36) of the plunger (32) is insertable into and moveable within the barrel (22) such that (a) a portion of the barrel (22) defines a closed-system syringe chamber (46) between the bottom barrel wall (28) and a lower surface (64) of the plunger head (36), and (b) a plunger-head annular seal (42) forms a fluid-tight seal between an outer surface (44) of the plunger head (36) and a cylindrical inner surface (26) of the barrel (22). A solid-dosage-form support disc (60, 360) is disposed below a bottom plunger wall (38) so as to define a grinding compartment (62) between the lower surface (64) of the bottom plunger wall (38) and an upper surface (66) of the solid-dosage-form support disc (60, 360), and is shaped so as to define a plurality of holes (68, 368) through the solid-dosage-form support disc (60, 360).

The invention relates to the field of medicine, in particular to solid dosage forms for the treatment of primary biliary cholangitis (PBC). The invention provides a modified release solid dosage form comprising two active pharmaceutical ingredients, obeticholic acid and ursodeoxycholic acid, arranged to release sequentially over time. The solid dosage form is designed to achieve a controlled, separate release of each API to provide a desired therapeutic profile.

Oral solid dosage forms including porcine thyroid powder and methods of making and using the oral solid dosage forms are disclosed.

A pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide is provided herein. A method for treating cancer is also provided herein, comprising a pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

This description relates to oral vaccine dosage forms and processes for producing oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) that contain an immunogenic quantity of at least one vaccine target molecule, with or without an adjuvant. Specifically, the applicants have discovered a combination of the composition of liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and manufacturing conditions for the dosage forms that can produce a lyophilized sublingual dosage form that has physical robustness, particle integrity, and antigen stability.

The present disclosure provides a solid pharmaceutical composition comprising of tafamidis, a solubilizer, and one or more pharmaceutically acceptable excipients; and process of making such compositions. The present disclosure also provides a solid pharmaceutical composition comprising of tafamidis indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

A screw pump for dispensing a solid dosage form (e.g., a drug or medicament) is configured as a unit for delivering the solid dosage form for dispensing. The screw pump includes a screw including a helical channel. A surface defining the helical channel has a profile at a location along a helical path of the helical channel, the profile being defined in a plane extending along a rotational axis of the screw pump and presenting a recess.

Provided are methods of preparing a homogeneous mixture from a solid dosage form in settings including a point of care setting. The methods include obtaining a solid dosage form comprising a drug product, adding the solid dosage form to a container having at least one flexible section, adding a liquid to the container, mixing the solid dosage form with the liquid to disperse, disintegrate, suspend, and / or dissolve the solid dosage form thereby creating a homogeneous mixture. Also provided are containers and devices for use in such methods.

The present invention relates to a film coated solid dosage form comprising a core and a film coat, wherein the core comprises a KAT6 inhibitor and at least one pharmaceutically acceptable excipient, and further wherein the film coated solid dosage form reduces frequency or severity of dysgeusia in a subject being treated for cancer with the KAT6 inhibitor.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the pharmaceutical oral solid dosage forms are disclosed.

The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder.

Disclosed herein are pharmaceutical oral solid dosage forms comprising at least one of phenobarbital and a phenobarbital salt, and methods of making and using the pharmaceutical oral solid dosage forms.

The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.

Provided herein are compositions and methods related to a solid dosage form comprising an absorption enhancer. The composition enhances the mucosal penetration and absorption of active ingredients.

To provide a means for stabilizing solid dosage forms containing bisbentiamine, thiamine disulfide, or bisibthiamine. [Solution] A solid preparation containing (A) bisbentiamine, thiamine disulfide, or bisibthiamine, and (B) one or more basic compounds selected from metal silicate salts and magnesium compounds.